Needham & Company Cuts Price Target on Flexion Therapeutics (FLXN) Following Top-Line FX006 Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Flexion Therapeutics Reports Top-Line Data From Pivotal Phase 2b Clinical Trial for FX006
September 8, 2015 4:01 PM EDTFX006 provides substantial and persistent pain relief compared to placebo; well-tolerated with safety profile comparable to placebo
Conference call scheduled for tomorrow, September 9, 2015, at 9:00 a.m. ET
BURLINGTON, Mass., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN) today reported top-line results from the first of two pivotal clinical trials of its lead drug candidate FX006 in patients with moderate to severe osteoarthritis (OA) knee pain. In this trial, 40 mg of FX006, compared to placebo (saline), demonstrated statistical significance in average pain relief over weeks 1 through 12 (p = 0.0012; 2-sided)... More
Flexion Therapeutics Reports Top-Line Data From Pivotal Phase 2b Clinical Trial for FX006
September 8, 2015 4:01 PM EDTFX006 provides substantial and persistent pain relief compared to placebo; well-tolerated with safety profile comparable to placebo
Conference call scheduled for tomorrow, September 9, 2015, at 9:00 a.m. ET
BURLINGTON, Mass., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN) today reported top-line results from the first of two pivotal clinical trials of its lead drug candidate FX006 in patients with moderate to severe osteoarthritis (OA) knee pain. In this trial, 40 mg of FX006, compared to placebo (saline), demonstrated statistical significance in average pain relief over weeks 1 through 12 (p = 0.0012; 2-sided)... More
